Literature DB >> 10052401

Polymerase chain reaction analysis of immunoglobulin gene rearrangement in cutaneous lymphoid hyperplasias. French Study Group for Cutaneous Lymphomas.

A Bouloc1, M H Delfau-Larue, B Lenormand, F Meunier, J Wechsler, E Thomine, J Revuz, J P Farcet, P Joly, M Bagot.   

Abstract

UNLABELLED: The differential diagnosis of cutaneous lymphoid hyperplasia and B-cell lymphoma may be difficult. Whether the detection of clonal immunoglobulin gene rearrangement in the cutaneous lesion is predictive of a malignant outcome remains controversial. We therefore studied cases of cutaneous lymphoid hyperplasia by polymerase chain reaction analysis.
DESIGN: Retrospective study of patients seen between 1988 and 1996.
SETTING: Two dermatology university departments. PATIENTS: Twenty-four patients with cutaneous lymphoid hyperplasias were included according to clinical, histopathological, and immunophenotypic criteria. MAIN OUTCOME MEASURES: Clinical, histopathological, and laboratory findings.
RESULTS: There were 13 men and 11 women (mean age, 49 years) who presented with erythematous or violaceous papules or nodules. The lesions were unique in 13 cases and multiple in 11 cases. All patients had immunochemical evidence of a mixed T- and B-cell infiltrate with polytypic B cells. Polyclonality was demonstrated in 23 patients, whereas a dominant B-cell clone was detected in 1 patient. No lymphoma developed during the follow-up (median, 4 years). In the same period, we studied 53 cases of B-cell lymphomas. Thirty-five (66%) of the 53 cases had a detectable clonal immunoglobulin gene rearrangement.
CONCLUSIONS: In the majority of our cases, polyclonality demonstrated by polymerase chain reaction analysis was in accordance with the diagnosis of cutaneous lymphoid hyperplasia. In 1 of the 24 patients, the presence of a B-cell clone could be evidenced. This fact did not modify the treatment as there were no histological or immunophenotypic signs suggestive of a lymphoma.

Entities:  

Mesh:

Year:  1999        PMID: 10052401     DOI: 10.1001/archderm.135.2.168

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas.

Authors:  M Nihal; D Mikkola; G S Wood
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Study of the reactive dendritic cells in small B-cell lymphoproliferations of the skin.

Authors:  Amélie Carbonnelle; Nadine Martin-Garcia; Nicolas Ortonne; Liliane Laroche; Martine Bagot; Valérie Molinier-Frenkel; Janine Wechsler
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

3.  Intracranial pseudolymphoma.

Authors:  A Donnet; N Horschowski; H Dufour; D Figarella-Branger; P A Bryon; F Berger; J R Harle; F Grisoli
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

4.  PCR Analysis of IgH and TCR-γ Gene Rearrangements as a Confirmatory Diagnostic Tool for Lymphoproliferative Disorders.

Authors:  Behzad Poopak; Ali Kord Valeshabad; Fazel Elahi; Hamid Rezvani; Gelareh Khosravipour; Mohammad Ali Jahangirpour; Shirin Bolouri; Tolou Golkar; Fatemeh Salari; Mohammad Shahjahani; Najmaldin Saki
Journal:  Indian J Hematol Blood Transfus       Date:  2014-05-04       Impact factor: 0.900

5.  Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice.

Authors:  Daniel López Aventín; Fernando Gallardo; Luis Colomo; Ester Moragón; María Carmen Vela; Xavier Duran Jordà; Beatriz Bellosillo; Ramon M Pujol
Journal:  Acta Derm Venereol       Date:  2021-05-19       Impact factor: 3.875

6.  The role of molecular pathology in the diagnosis of cutaneous lymphomas.

Authors:  Philipp W Raess; Adam Bagg
Journal:  Patholog Res Int       Date:  2012-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.